Literature DB >> 11395204

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

K J Stittelaar1, T Kuiken, R L de Swart, G van Amerongen, H W Vos, H G Niesters, P van Schalkwijk, T van der Kwast, L S Wyatt, B Moss, A D Osterhaus.   

Abstract

Modified vaccinia virus Ankara (MVA)-based recombinant viruses have been shown to be potent vaccine candidates for several infectious and neoplastic diseases. Since a major application of these live, replication-deficient vectors would be their use in immunocompromised or potentially immunocompromised individuals, a preclinical safety study was carried out. Macaques were inoculated with high doses of MVA (10(9)) via various routes, after immune-suppression by total-body irradiation, anti-thymocyte globulin treatment, or measles virus (MV) infection. No clinical, haematological or pathological abnormalities related to MVA inoculation were observed during a 13-day follow-up period. The presence of MVA genomes was demonstrated by nested PCR during the course of the experiment in all macaques, but from none of these animals replication competent MVA could be reisolated. These data suggest that MVA can safely be used as a basis for recombinant human vaccines, and that it is also safe for use in immunocompromised individuals.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11395204     DOI： 10.1016/s0264-410x(01)00075-5

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  67 in total

1.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

4.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

5.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

6.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

7.  Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Ondraya Espenshade; Jocelyn Bassler; Kathy Gong; Shuling Lin; Elizabeth Peters; Lowrey Rhodes; Yvette Edghill Spano; Peter M Silvera; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205

8.  Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice.

Authors:  Valérie Abadie; Olivia Bonduelle; Darragh Duffy; Christophe Parizot; Bernard Verrier; Béhazine Combadière
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

9.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

10.  MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

Authors:  Joost H C M Kreijtz; Yasemin Suezer; Gerrie de Mutsert; Geert van Amerongen; Astrid Schwantes; Judith M A van den Brand; Ron A M Fouchier; Johannes Löwer; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.